November 3, 2015 / 1:38 PM / in 3 years

Johnson & Johnson HIV combination succeeds in mid-stage study

Nov 3 (Reuters) - A cocktail of Johnson & Johnson’s HIV compound and an experimental drug from ViiV Healthcare met the main goal of a mid-stage study, becoming the second combination to do so.

J&J’s pharmaceuticals business chairman, Paul Stoffels, said the company hopes to have the combination on the market by 2020.

The combination of J&J’s rilpivirine and ViiV’s cabotegravir showed that it was as good as three pills a day at maintaining minimal viral levels in HIV-infected patients when given together every four or eight weeks.

J&J is co-developing this combination with ViiV, which has GlaxoSmithKline Plc, Pfizer Inc and Shionogi & Co Ltd among its shareholders.

A late-stage study of a second combination, J&J’s rilpivirine and ViiV’s dolutegravir, has already begun. The companies are planning to develop other combinations. (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below